RFA-AT-25-003 HEAL PREP R15 eligibility Guide
Updated 12 official sources
Quick Answer: RFA-AT-25-003 is the HEAL Initiative PREP R15 route for basic and mechanistic pain research at R15-eligible institutions.
Full answer and how we checked it
It is clinical trial optional, requires a domestic research partnership, requires student engagement, and does not support efficacy or effectiveness trials. The 2026 decision turns on 7 checks.
Who this is for: R15-eligible undergraduate-focused institutions, health professional schools, graduate schools, pain researchers, collaborator institutions, research deans, and sponsored-research teams deciding whether the PREP route fits.
Data note: This guide uses NIH RFA-AT-25-003, NCCIH's PREP FAQ, NIH HEAL funding pages, Grants.gov listing 358090, NIH RePORTER award records pulled on October 6, 2026, and Grantsights award-data signals; the NOFO dates were re-verified on October 1, 2026.
In this guide
- Source Check
- 7 RFA-AT-25-003 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- Who PREP Has Funded: 3 Awards in NIH RePORTER
- The $6 Million Test and the PI Rules
- 4 Attachments That Get an Application Withdrawn
- How PREP Applications Are Scored
- HEAL Data Commitments to Budget For
- What NIH Doesn't Tell You
- 6 Evidence Assets That Make This R15 Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day PREP Readiness Plan
- 7 PREP Checks Before October 27, 2026
- Sources
RFA-AT-25-003 is not a general pain research grant. According to NIH in RFA-AT-25-003 (opens in a new tab), the route supports basic and mechanistic pain research from R15-eligible institutions, builds research partnerships, and strengthens student research experience at the applicant institution.
The applicant question is narrow: does the PI sit at the right kind of institution, can the pain research be led there, and does the partnership strengthen the R15 program without taking over the project?
Use this guide with the live HEAL PREP R15 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, Rare Disease Preclinical R21 guide, the parent NIH R15 AREA guide, and the Grantsights grant database.
Source Check
Checked October 2026.
As of October 1, 2026, October 27, 2026 is the only due date left in RFA-AT-25-003 (opens in a new tab), and it covers new and resubmission applications. Applications on that date go to scientific merit review in March 2027 and council in May 2027, with an earliest start of July 2027. The NOFO expires November 24, 2026, and NIH says no late applications will be accepted. A late-November date in another listing is the expiration date, not a second deadline.
The active NOFO allows clinical trials, but not trials that primarily test safety, tolerability, efficacy, or effectiveness of pharmacologic, behavioral, biologic, surgical, or device interventions. The funded fit is still small-scale basic or mechanistic pain research led by an R15-eligible PI.
The money is small. NIH says the HEAL Initiative intends to commit an estimated $1.25 million to fund up to three awards per year in FY2026 and FY2027. With up to three awards a year, the competition is tight, and a team that misses October 27 has no later PREP date under this NOFO. The realistic choices are a final push now or a different route, such as the parent R15.
Get grant deadline alerts by email
About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.
No spam. Unsubscribe anytime.
7 RFA-AT-25-003 Eligibility Stop Checks
PREP is a pain research and institutional-capacity route, not a way to route any pain-related clinical study.
| Stop check | Strong R15 signal | Red flag |
|---|---|---|
| Institution | R15-eligible applicant institution | Research-intensive institution leads in practice |
| PI role | PI has primary appointment at eligible institution | Partner drives the science |
| Pain fit | Basic or mechanistic pain research is central | Pain is a side note |
| Student role | Students are directly engaged in research | Student role is symbolic |
| Partnership | Separate U.S. domestic institution subaward is included | No subaward or unclear partner |
| Trial scope | Mechanistic trial, or BESH as non-trial human subjects work | Safety, tolerability, efficacy, or effectiveness trial |
| Budget split | Applicant institution leads most work | Subaward exceeds one third |
| Source date | October 27, 2026 due date is used | Team treats November 24 as the due date |
| Attachments | Team Management Plan, partner letter, and provost support are ready | Required attachments are left until the end |
An R15 application can pair strong science with a weak institution story. That usually hurts because R15 routes care about the research environment, not only the project.
5 Source Facts Applicants Should Know
According to NIH in RFA-AT-25-003 (opens in a new tab), the funding number is RFA-AT-25-003, the mechanism is R15, the clinical-trial status is optional, and the next listed standard due date is October 27, 2026. According to NCCIH's PREP FAQ (opens in a new tab), investigators from undergraduate-focused institutions, health professional schools, or graduate schools are eligible if they meet R15 requirements.
According to NIH, a PREP application must provide evidence of a subaward to a separate institution, and the project and two-thirds of the total project budget are expected to be directed by the R15-eligible PI or institution. Applicants may request up to $375,000 in direct costs for the full project period.
| Fact | Source-backed read |
|---|---|
| Funding number | RFA-AT-25-003 |
| Mechanism | R15 Academic Research Enhancement Award |
| Clinical trial status | Optional, with strict trial type limits |
| Partnership | Separate U.S. domestic subaward required |
| Award cap | $375,000 direct costs for the full project period |
| Live deadline | October 27, 2026 |
| Expiration | November 24, 2026 |
Who PREP Has Funded: 3 Awards in NIH RePORTER
Grantsights checked RFA-AT-25-003 and its predecessor against NIH RePORTER award records on October 6, 2026. NIH posted RFA-AT-25-003 on January 8, 2025 as a reissue of RFA-AT-25-001 (opens in a new tab), so the two notices are one program. A search of the NIH RePORTER project API (opens in a new tab) by funding opportunity number returned 3 awards, worth $1,693,315 in total costs. The wider assistance-listing figures above cover far more than PREP.
| Fiscal year | Recipient | State | Notice | Project | Total costs |
|---|---|---|---|---|---|
| 2025 | Middlebury College (opens in a new tab) | VT | RFA-AT-25-001 | Pain modulation by spinal cord stimulation | $540,427 |
| 2026 | Fairleigh Dickinson University (opens in a new tab) | NJ | RFA-AT-25-003 | Central sensitization in benign urologic disease | $560,491 |
| 2026 | Virginia College of Osteopathic Medicine (opens in a new tab) | VA | RFA-AT-25-003, resubmission | Back pain injury mechanisms | $592,397 |
Grantsights analysis of these NIH RePORTER records shows 4 things the notice doesn't say.
- Each award is one record for the whole project. Specifically, Fairleigh Dickinson University's urologic pain project carries $560,491 on a single FY2026 record whose budget period runs from August 2026 to July 2029. The amounts in the table are full 3-year totals, not one year.
- Funded totals run $540,427 to $592,397. That range fits the $375,000 direct-cost cap plus the applicant's F&A. RePORTER's direct-cost field on these awards runs higher, $429,703 to $461,996, most likely because the required subaward's own F&A is counted inside direct costs. Under NOT-OD-05-004 (opens in a new tab), NIH leaves consortium F&A out when it checks a direct-cost limit, so budget the cap on the prime's direct costs plus the partner's direct costs.
- Fewer awards than the notice allows. NIH said it would fund up to 3 awards a year. According to NIH RePORTER, PREP made 1 award in FY2025 and 2 in FY2026, and the 2 FY2026 awards total $1,152,888. So far, each of the 2 review rounds has produced 1 or 2 awards, not 3.
- A resubmission can win. The Virginia College of Osteopathic Medicine award carries an A1 suffix, so NIH funded it on the second submission. October 27, 2026 accepts resubmissions, which means a team scored in the March 2026 review round still has one more try under this notice. The NIH resubmission guide covers the Introduction page that has to go with it, and the parent R15 AREA guide covers the fallback if the score was far off.
All 3 recipients fit the R15 profile the notice describes: a liberal arts college, a private university, and an osteopathic medical school. RePORTER lists NCCIH as the administering institute and NINDS as the funding institute on all 3, which helps when searching RePORTER for PREP projects by institute.
The $6 Million Test and the PI Rules
Eligibility turns on 2 dollar and appointment tests that the provost has to sign off on. For an undergraduate-focused institution, NIH says all non-health-professional components combined must not have received more than $6 million per year in NIH support (direct plus F&A) in 4 of the last 7 years, and the eligible school or college must enroll more undergraduates than graduate students. For a health professional school or graduate school, the same $6 million test applies to all components of the institution combined.
| Rule | What RFA-AT-25-003 (opens in a new tab) says |
|---|---|
| NIH funding ceiling | No more than $6 million per year in 4 of the last 7 years |
| PI appointment | Primary appointment at an R15-eligible institution, for every PD/PI on an MPI team |
| Active NIH grants | A PD/PI cannot hold an active NIH research grant, including another R15, at the time of a PREP award |
| Partner | At least 1 separate U.S. domestic institution through a subaward, capped at one third of the total budget |
| Foreign subawards | Not allowed; an application with one is noncompliant |
| Budget form | Modular up to $250,000 total direct costs; R&R budget from $250,001 to $375,000 |
| Inflation | No annual inflationary increases |
The active-grant rule is the one teams underestimate. A PI who is key personnel on a colleague's R01 can still apply, but a PI who will be PD/PI of their own active NIH research grant when the PREP award is made cannot receive it.
4 Attachments That Get an Application Withdrawn
Missing paperwork ends a PREP application before review. NIH lists these as required, and an application without them is withdrawn:
- Facilities & Other Resources. It must profile the institution's students, estimate how many went on to advanced health-science degrees in the last 5 years, and show that personnel from the R15-eligible institution make up a two-thirds majority of the project team.
- Team-Management-Plan.pdf. Three pages maximum. It covers organizational structure, shared decision making, and how credit and intellectual property will be shared with students.
- ProvostLetter.pdf. Signed by the provost or a similar institution-wide official, attesting to the $6 million test. MPI applications need one from each institution.
- CollaboratorLetter_Initials.pdf. One signed letter from each subaward collaborator.
Two smaller instructions also matter. Each PI's biosketch personal statement should summarize experience supervising students and flag which publications had student co-authors. Students must be paid for their research time under institutional policy; NIH does not fund undergraduate stipends on R15 awards.
How PREP Applications Are Scored
PREP review is not a standard R01 read. NIH tells reviewers to weigh scientific contribution together with research opportunities for students and the strength of the institution's research environment. The NOFO also says a solid project that is not new in concept can still be a strong R15 application if it gives students real primary research.
| Review element | What reviewers are asked to judge |
|---|---|
| Significance | Rigor of the scientific background and the award's effect on the institution's research environment |
| Approach | Whether students get a rigorous experience in execution, analysis, and reporting |
| Team Management Plan | Whether R15-institution students form two thirds of the team and how the partnership supervises them |
| Investigators | Track record supervising students, not only research output |
| Environment | Likely availability of students and plans to tell them about the project |
The common mistake is writing a training plan. NIH says applications should not include didactic training, seminars, or independent student projects, because PREP funds pain research rather than training.
HEAL Data Commitments to Budget For
HEAL awards carry data rules beyond the standard NIH Data Management and Sharing Plan. The NOFO requires plans to deposit data in a HEAL-compliant repository, register the study on the HEAL platform within 1 year of award, and submit HEAL study-level metadata within 1 year. Pain studies with human participants must plan to use the HEAL core Common Data Elements (opens in a new tab), and copyrighted questionnaires need licenses before data collection starts. Budget staff time for this, because a small R15 team often has no data manager. The rules are summarized on the HEAL data sharing compliance page (opens in a new tab).
What NIH Doesn't Tell You
Within 21 days, answer 4 practical questions. First, don't assume R15 eligibility. The institution, campus identifiers, PI appointment, active NIH support, and eligibility letter can decide the application before the science does.
Second, the partner should add expertise without taking control. For example, one college in rural Ohio studying chronic musculoskeletal pain could partner with a data science lab at a separate university, but the R15-eligible PI must still lead the research program and student experience.
Third, trial scope is easy to misread. The RFA allows mechanistic clinical trials. It does not support clinical trials primarily testing safety, tolerability, efficacy, or effectiveness. NIH used to count Basic Experimental Studies with Humans (BESH) as clinical trials, but that changed after this RFA was posted: under NOT-OD-26-067 (opens in a new tab) (April 6, 2026), NIH no longer characterizes BESH as clinical trials for competing applications due on or after May 25, 2026. For the October 27, 2026 round, a BESH study is human subjects research without a clinical trial designation, so it skips ClinicalTrials.gov registration and results reporting but still follows human subjects protections and the NIH Data Management and Sharing Policy.
Fourth, student engagement has to be concrete. Don't submit a PREP application if students are only listed as future helpers. The work plan should state what they will do, how they will be supervised, and what research skills they will gain.
6 Evidence Assets That Make This R15 Stronger
Within 21 days, build 6 evidence assets. Asset 1 is an institutional eligibility memo signed by a provost or comparable official. NIH requires a signed eligibility letter.
Asset 2 is a student engagement table. It should list student types, roles, research tasks, supervision, meeting cadence, presentation plans, authorship expectations, and safety or human-subjects training.
Asset 3 is a partner scope table. Include each subaward institution, expertise, resources, deliverables, budget share, and why the work strengthens the R15 program rather than replacing it.
Asset 4 is a pain-mechanism map.
Asset 5 is a trial-type decision. If humans are involved, decide whether the study is a mechanistic trial, BESH (no longer a clinical trial for due dates on or after May 25, 2026), observational, secondary analysis, or nonresponsive. That choice drives how you fill out the PHS Human Subjects and Clinical Trials Information form.
Asset 6 is a 3-year feasibility plan. NIH says projects should have objectives that can be completed within the proposed 3-year grant period.
5 Route Choices Before Drafting
Within 21 days, compare 5 routes.
| Route | Better first read when... | Why |
|---|---|---|
| RFA-AT-25-003 PREP R15 | R15 institution, pain mechanism, students, and partner all fit | Route matches |
| Parent R15 | HEAL pain focus does not fit | R15 structure may still fit |
| R21 or R01 | Institution is not R15-eligible | Other mechanism needed |
| Clinical trial route | Efficacy or effectiveness is central | PREP does not fit |
| Training grant | Main product is training, not research | PREP is a research grant |
The strongest applicants can say why PREP is the best route, not merely why the PI wants pain funding.
6 Bad-Fit Signals
First, the applicant institution is not R15-eligible. Second, the PI's appointment does not match the route. Third, pain is not central.
Fourth, the partner institution runs most of the science. Fifth, student engagement is thin. Sixth, the proposed clinical trial tests efficacy, effectiveness, safety, or tolerability.
Those stop checks matter for trust. A serious page should tell users when to leave.
21-Day PREP Readiness Plan
Days 1 through 3 should confirm R15 eligibility, source status, deadline, clinical-trial scope, and the PI's appointment. Days 4 through 7 should write the pain-mechanism statement and student-role table.
Days 8 through 12 should secure partner scope, subaward amount, letters, and team management logic. Days 13 through 16 should decide trial type and nonresponsive risk. Days 17 through 21 should draft the provost letter, facilities statement, and program-staff questions.
7 PREP Checks Before October 27, 2026
There's one PREP due date left, so run these 7 checks before the team commits to it. Each row ties back to RFA-AT-25-003 (opens in a new tab) or to the RePORTER check above.
| Check | What to confirm | Where it comes from |
|---|---|---|
| Eligibility | The provost can sign that NIH support stayed at or under $6 million a year in 4 of the last 7 years | RFA-AT-25-003 eligibility rules |
| PI status | No PD/PI will hold an active NIH research grant, including another R15, when the award is made | RFA-AT-25-003 eligibility rules |
| Date | October 27, 2026 by 5:00 PM local time, with no later PREP date under this notice | RFA-AT-25-003 key dates |
| Budget | $375,000 direct for the full project, with subawards at no more than one third of the total | RFA-AT-25-003 award budget |
| Trial scope | Mechanistic trial or BESH study (BESH not treated as a trial after May 25, 2026), with no efficacy, effectiveness, safety, or tolerability trial | RFA-AT-25-003; NOT-OD-26-067 |
| Award size | $540,427 to $592,397 in total costs, the range of the 3 funded PREP projects | NIH RePORTER, October 6, 2026 |
| Next action | Submit, ask NCCIH program staff a scope question, or move the project to the parent R15 | Route comparison above |
Sources
- NIH RFA-AT-25-003 (opens in a new tab)
- NCCIH PREP FAQ (opens in a new tab)
- NIH HEAL funding opportunities (opens in a new tab)
- NIH HEAL data sharing compliance (opens in a new tab)
- NIH NOT-OD-26-067 on Basic Experimental Studies with Humans (opens in a new tab)
- NIH RFA-AT-25-001, the first PREP notice (opens in a new tab)
- NIH RePORTER project search API (opens in a new tab), queried October 6, 2026 for RFA-AT-25-001 and RFA-AT-25-003
- NIH NOT-OD-05-004 on consortium F&A and direct-cost limits (opens in a new tab)
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open HEAL PREP record
Check October 27 2026 timing, $375K cap, R15 eligibility, domestic partner, and one-third subaward limit.
Compare preclinical R21
Use when the project is a small exploratory therapeutics study rather than an R15 institution route.
Compare trial planning
Use when the human study is an efficacy or effectiveness trial instead of mechanistic pain research.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does RFA-AT-25-003 fund?
It funds HEAL PREP R15 pain research at R15-eligible institutions, with student engagement and a required domestic research partnership.
Are clinical trials allowed?
Yes, but only mechanistic trials fit. Safety, tolerability, efficacy, or effectiveness trials are nonresponsive. For the October 27, 2026 due date, NIH no longer treats basic experimental studies with humans (BESH) as clinical trials (NOT-OD-26-067), so a BESH project goes in as non-trial human subjects research.
What is the next deadline?
October 27, 2026 is the last due date, for new and resubmission applications alike. The NOFO expires November 24, 2026, and NIH accepts no late applications.
What partnership is required?
The application must include at least one subaward to a separate U.S. domestic institution, and subawards cannot exceed one third of the total budget.
Who should skip this route?
Skip it if the institution is not R15-eligible, student engagement is weak, pain research is not central, or the clinical trial is efficacy-focused.
Last updated October 12, 2026. Corrected October 11, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-338 academic industrial R01 eligibility Guide
PAR 25 338 academic industrial guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
NIH ALS Expanded Access U01 Eligibility
NIH ALS expanded access U01 guide for RFA-NS-26-001, trial-site eligibility, small-business IND sponsor rules, and route fit.
NIH AMP SCZ DPACC U24 eligibility Guide
NIH AMP SCZ DPACC U24 guide for single-source eligibility, June 9 2026 timing, $5M award signal, no-trial status, and NIMH route choices.